{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093114","form_type":"8-K","ticker":"LFST","cik":"0001845257","company_name":"LifeStance Health Group, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.868700+00:00","generated_at":"2026-05-31T11:16:57.463406+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"LifeStance Q2 revenue up 20% to $312M; raises FY2024 guidance on strong margins","bullets":["Revenue $312.3M (+20% YoY); net loss narrowed to $23.3M from $45.5M; Adjusted EBITDA $28.6M (+103%).","Center Margin improved to 31.3% of revenue (28.1% prior year); clinician base up 14% to 6,984.","FY2024 guidance raised: revenue $1.2B-$1.242B, Adjusted EBITDA $90M-$100M; expects positive free cash flow.","Q3 2024 guidance: revenue $290M-$310M, Adjusted EBITDA $15M-$21M.","Cash $87M, net debt $279.5M; operating cash flow $44.1M in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093114","json":"https://secwatch.observer/filing/0000950170-24-093114.json","markdown":"https://secwatch.observer/filing/0000950170-24-093114.md","text":"https://secwatch.observer/filing/0000950170-24-093114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845257/000095017024093114/0000950170-24-093114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845257/000095017024093114/lfst-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:16:57.463406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}